An observational study in Myotonic Dystrophy, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.
Sponsored by Wake Forest University Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myotonic Dystrophy with a site in United States — 23 open to participants now, 27 under way, 4 of them phase 3. Myotonic Dystrophy · United States.
Among the 43 studies in Myotonic Dystrophy with a site in United States, this one is the 18th largest by planned enrollment of the 21 observational ones that give a count, is one of 6 that started in 2025, is one of 21 observational ones, reaches primary completion later than 16 of the 26 other live ones, and was the 37th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →23 of the 43 studies in Myotonic Dystrophy with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 14+ · Healthy volunteers
Virginia Commonwealth University · Sites in United States
Ages 18–70
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Dyne Therapeutics · Sites in United States, Australia, Belgium and 9 more countries
Ages 16+
Sanofi · Sites in United States, Argentina, Australia and 3 more countries
Ages 10–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 6
First in 2000; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 75 is below the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Median enrollment 46 across the 22 interventional studies, 125 across the 21 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 43 have an industry lead sponsor. The 10 most frequent:
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
Wake Forest University Health Sciences has 2 studies filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
9 of the studies in Myotonic Dystrophy with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05004129Phase 3AMO Pharma LimitedSafety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy | 2026-12-31 |
| NCT05020002Massachusetts General HospitalExtracellular RNA Biomarkers of Myotonic Dystrophy | 2026-12 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 9 to your calendar (.ics) → With an account.
Among the 43 studies in Myotonic Dystrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatments are available that alter the course of the disease, but ongoing clinical trials are underway.
Past and current clinical trials in DM1 have relied on muscle biopsies to evaluate pathology and measure drug activity. However, this method is invasive and inefficient for long-term monitoring. What is lacking are non-invasive imaging biomarkers capable of providing comparable data, which would enhance trial planning, accelerating drug development while reducing morbidity and costs. Non-invasive muscle imaging, particularly through Quantitative Magnetic Resonance Imaging (qMRI), is essential to better understand how DM affects muscle structure. Moreover, the relationships between Magnetic Resonance Imaging (MRI) measures, disease severity, and Ribonucleic Acid (RNA) splicing outcomes from muscle tissues in the same DM patients are not yet known. As MRI has been relatively unstudied in DM, there needs to be a comprehensive baseline characterization of muscle structure and its relationship to clinical endpoints and RNA-associated disease processes. This will help evaluate the potential of qMRI as a biomarker of disease severity in DM.
The selection criteria will minimize the heterogeneity effects and mirror DM subjects likely to be selected for clinical trials, who are typically mildly to moderately affected. Subjects will be recruited from the Wake Forest Neuromuscular Clinic and nearby medical centers (Duke University, UNC Chapel Hill, and Atrium Health in Charlotte).
Since DM2 is rarer than DM1 and patients live across the country, additional recruitment efforts will target DM2 subjects through the Myotonic Dystrophy Foundation Family Registry (MDFR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
DM subjects
Control subjects
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Age 18 - 65 years 2. Diagnosis of DM1 or DM2 by clinical or genetic criteria. If DM1 or DM2 was diagnosed by clinical criteria, a first-degree relative must have genetic testing confirmation and sign a genetic consent form to release their genetic information. 3. Clinically affected, as defined by muscle weakness or myotonia 4. Ambulate independently (a walker is not permitted) 5. Able to provide informed consent for participation in the study
1. Age 18 - 65 years old 2. Healthy as defined by no significant medical or neurological conditions 3. Able to provide informed consent for participation in the study
Contractile muscle volume (CMV, cm3)
Contractile muscle volume (CMV, cm3) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments
Time frame: Baseline
Muscle fat fraction (MFF, %)
Muscle fat fraction (MFF, %) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments
Time frame: Baseline
Average measures of Manual muscle testing (MMT)
MMT will be performed in 7 different muscle groups (hip flexors, hip abductors, knee flexors, knee extensors, ankle dorsiflexors, plantar flexors, and neck flexor) in standardized positions. Each group will be scored using a 13-point modified Medical Research Council (MRC) scale and standardized positions. Where 0 is paralysis, 1 is a flicker/trace contraction, 2 is movement with gravity eliminated, 3 is movement against gravity, 4 is movement against some resistance, and 5 is normal strength against full resistance - higher scores denoting stronger muscles
Time frame: Baseline
Average measures of Quantitative Muscle Testing (QMT)
QMT of the leg muscles (hip flexors, hip abductors, knee extensors, knee flexors, ankle dorsiflexors, and plantar flexors) will be performed using a hand-held dynamometer in standardized positions. During the measurement, the subject will be instructed to increase to maximum exertion over a few seconds without jerking, and to maintain this effort until the evaluator give the command to relax (3-5 seconds). The clinical evaluator will hold the dynamometer stable, and the subject will be asked to push as hard as possible against the applicator, but with a slow build-up of force. The subject will perform each push three times with up to a 30-second pause between each trial. The average and highest scores obtained will be used for analysis.
Time frame: Baseline
Average measures of grip strength (pounds or kilograms)
Use Jamar handgrip dynamometer to test handgrip strength. We will test each subject three trials, starting with a dominant hand first, then a non-dominant hand. An average score in each hand will be used for analysis. Higher scores denote stronger grip strength - It works by squeezing the device to its maximum, revealing strength in pounds or kilograms (up to 200 lbs/90 kg)
Time frame: Baseline
Average measures of pinch strength
The subject will perform quantitative pinch strength testing with a pinch gauge - higher numbers denote stronger pinch strength - Normal range: 10-20 pounds of force
Time frame: Baseline
The 6-minute walk test (6MWT) times
walking ability in muscular dystrophies, the 6MWT probably offers the best combination of reliability, sensitivity, clinical significance, and feasibility for clinical trials. The procedures will be performed in a standardized manner following the guidelines of the American Thoracic Society. Lower times denote faster walks
Time frame: Baseline
gait speed times
Subjects will be instructed to walk at maximum speed in a long corridor with an even surface over 10 meters with a still-standing start and a "flying" finish. The subjects will be instructed to continue walking to a target 2.5 meters beyond the mark at 4 and 10 meters, where the clinical evaluator stands. The time will be measured with the stopwatch and is started on the word "Go" ("Ready-Set-Go") until subject reaches a 4 and 10-meter mark. Lower times denotes faster speeds
Time frame: Baseline
step test amount
The subject will stand unsupported 5 cm in front of a block (maximum height 10 cm) and make as many "full steps" as possible during 15-second period. One step comprises placing one foot fully up onto and then down off the block. Both legs will be tested, one foot at a time. The subject will allow some practice steps and then one test attempt per leg. If balance is lost during the trial, the completed steps will be reported. Clinical Evaluator will kneel by the block and holds it to ensure it remains steady during the test. higher scores denotes better balance and strength
Time frame: Baseline
sit-to-stand test amount
The test will be administered using a standard chair with a seat height of 17 inches (43.2 cm) and rubber tips on the legs. The test begins with the subject seated in the middle of the chair, back straight, feet approximately shoulder-width apart and place on the floor at an angle slightly back from the knees, with one foot slightly in front of the other to help maintain balance when standing. Arms are crossed and held against the chest. At the signal "go," the subject will rise to a full stand and then return to the initial seated position. The subjects will be encouraged to complete as many full stands as possible within a 30-second time limit. The score will be the total number of stands executed correctly. Incorrectly executed stands will not be counted - higher scores denotes better balance and strength
Time frame: Baseline
Short Physical Performance Battery (SPPB) Scores
The physical performance will be assessed using the expanded SPPB commonly used in research. The SPPB measures physical function using three components: 4-meter natural gait speed, time to complete five chair rises, and standing balance with a narrow base of support. Each component is scored on a 0-4 scale and summed for an overall score range of 0-12. The SPPB is a reliable and validated measure of physical function in the older population that can be collected safely and easily at clinic, home, or hospital setting. Overall scores and components of SPPB are highly predictive of clinical outcomes, including disability, hospitalization, and death. The SPPB is also sensitive to change over time and responsive to exercise training. A clinically meaningful but small change in SPPB score is 0.5 units, and a substantial change is 1.0 units
Time frame: Baseline
Nine-Hole Peg Test (9HPT) times
The test will evaluate upper extremity function, specifically fine dexterity, and coordination. test each subject once, starting with a dominant hand first, then a non-dominant hand. One practice trial (per hand) should be provided before timing the test. The subjects will be instructed to pick up the pegs one at a time using one hand only and put them into the holes one at a time and return each of them to the container. Lower times denotes higher dexterity and coordination
Time frame: Baseline
Time Up and Go (TUG) times
TUG is used to evaluate various aspects of dynamic stability related with falls. A TUG time \> 14 seconds is associated with falls in DM1. The TUG includes rising from a chair, walking 3 meters, turning, walking back, and sitting down. The TUG shows good test-retest reliability (ICC \> 0.8) in individuals with DM1 - scores under 10 seconds are normal, under 20 seconds indicate good mobility, while over 30 seconds suggests significant impairment, requiring assistance and indicating a high fall risk, with 14+ seconds signaling increased risk.
Time frame: Baseline
DM1-Activity and Participation Scale (DM1-Activ) Scores
The DM1-Activ is a 25-item instrument, designed to assess activity limitations in individuals with DM1. It has been validated as a disease-specific PRO measure for assessing activity limitations in DM1 with good internal consistency and constructive validity. It captures the impact of DM1 on daily activities and physical function, making it a valuable tool for clinical trials and disease monitoring - using response options from "impossible" to "without difficulty"
Time frame: Baseline
Patient-Reported Outcomes Measurement Information System (PROMIS-10) Scores
assessing global health (physical and mental) and social well-being. It evaluates health symptoms and quality of life sub-domains such as pain, fatigue, physical activity, and global health (GH). PROMIS is well-validated with chronic neurological conditions, demonstrating strong internal consistency and cross-sectional validity. use PROMIS-10, a 10-item questionnaire, assessing multiple health domains. This tool provides less ceiling effect and has been accepted as a key outcome in the NINDS Common Data Elements. The raw responses (1-5 scale) are converted to these T-scores, allowing for interpretation like scores above 60 being moderately worse than average and below 40 being significantly better.
Time frame: Baseline
Brief Pain Inventory (BPI) Scores
The short form BPI is designed to measure the interference pain has with patient daily activities. These scales were selected based on their validity, simplicity, ability to detect change in pain with treatment, patient relevance, reliability, test-retest scores, and their previous use in pain studies of the myotonic dystrophy population - uses 0-10 scales to quantify pain severity (worst, least, average, current) and interference with daily life (mood, activity, sleep, etc.), with higher numbers indicating worse pain or interference
Time frame: Baseline
Checklist Individual Strength (CIS-fatigue) Scores
The level of fatigue will be assessed using the CIS 'fatigue severity' subscale. It measures the experience of fatigue-associated problems during the past 2 weeks. The CIS-fatigue severity subscale contains eight items (items 1, 4, 6, 9, 12, 14, 16, 20) scored on a 7-point Likert scale. Scores can range between 8 and 56 with higher scores indicating higher levels of fatigue and scores of \> 35 or more are indicated severe fatigue
Time frame: Baseline
Muscular Impairment Rating Scale (MIRS) Scores
MIRS is a quick, simple, and reliable scale to evaluate muscle impairment in DM1. It has been validated with motor activities and functional status index questionnaire. It is a five-ordinal scale with the definition of the grades as follows: 1=no impairment; 2=minimal signs, as ptosis and nasality, no distal weakness except long finger flexor weakness; 3=distal weakness, no proximal weakness except in elbow extensors; 4=mild to moderate proximal weakness; and 5=severe proximal weakness. This will be tested for DM1 subjects only. The MIRS is useful to monitor severity stages of disease progression and to identify homogeneous groups of patients for trials
Time frame: Baseline
presence of edema-liked changes
MRI Short Tau Inversion Recovery (STIR) sequence data will be evaluated for edema-like changes by assessing the presence or absence of signal hyperintensity in each muscle by a consultant radiologist - STIR (Short Tau Inversion Recovery) sequence is a special MRI technique that suppresses (blacks out) the signal from fat, making it excellent for highlighting fluid-filled tissues like edema (swelling), inflammation, tumors, and stress fractures, especially in bone marrow and soft tissues, because it makes these pathologies appear bright against the dark background of fat.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.
Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's planned 48 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →